必存联合阿加曲班对进展性卒中治疗临床研究  

Clinical Study on Effect of Edaravone and Argatroba Injection for Acute Stroke in Progression

作　　者：魏微[1] 张微微[1] 王娟[1] 

机构地区：[1]北京军区总医院神经内科,北京市100700

出　　处：《医药论坛杂志》2010年第15期8-9,12,共3页Journal of Medical Forum

摘　　要：目的评价必存联合阿加曲班注射液治疗进展性卒中临床疗效。方法选择发病在72h内的进展性卒中患者102例,随机分成治疗组48例和对照组54例。治疗组给予必存30mg加入生理盐水100mL静脉滴注,2次/d,连用7d;给予阿加曲班注射液60mg,24h内泵入,24h后给予10mg,2次/d静点;对照组仅用同剂量、同疗程的阿加曲班。将两组病例进行美国国立卫生院卒中量表(NIHSS)评分及日常生活能力(B I)评分。结果治疗组与对照组NIHSS评分和B I评分在治疗后14d、1个月均有统计学差异(P<0.05)。结论治疗进展性卒中应用必存和阿加曲班联合优于仅用阿加曲班治疗进展性卒中的疗效。Objective To investigate the efficacy of Edaravone combined with Argatroba for progressive stroke.Methods Totally 102 patients with acute stroke in progression were randomly divided into 2 groups.Therapy group（48cases）were treated with Edaravone combined with Argatroba for 7 days.Control group（54 cases） were treated with Argatroba.The effect were evaluated by index of NIHSS and BI before therapy and 14days,1month after treatment,respectively.Results There were significant differences between the two groups on index of NIHSS and BI at 14days and 1 month after treatment（P〈0.05）.Conclusion Edaravone combined with Argatroba is effective on controlling acute stroke in progression.

关 键 词：进展性卒中 必存 阿加曲班 

分 类 号：R743.3[医药卫生—神经病学与精神病学]